Baird analyst Michael Halloran downgrades A.O. Smith (NYSE:AOS) from Outperform to Neutral and announces the price target from $72 to $60.
Analyst Expectations for Intra-Cellular Therapies’s Future
Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…